Neovacs obtains FDA "Fast Track" designation for IFNα Kinoid in Lupus (SLE)
Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today ann…
Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today ann…
Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today ann…
Neovacs (Alternext Paris: ALNEV, PEA-eligible SMEs), a leader in active immunotherapy for the treatment of autoimmune di…
Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announ…
Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announ…
Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announ…
. - Strong improvement in net results - Balance sheet strengthened through capital increase of EUR7.5 million and sign…
NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced…
NEOVACS (Alternext Paris: ALNEV), today announced the signature of an exclusive licensing agreement with Chong Kun Da…
NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced…